CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary genome editing technology that enables precise modifications of DNA sequences in living cells and organisms. This programmable system has transformed preclinical research by providing unprecedented ease and control for creating disease models, validating therapeutic targets, and developing novel treatment strategies across multiple species and applications in contract research settings.
Technology Fundamentals and Mechanism
CRISPR refers to the various CRISPR-Cas9 and -CPF1 systems that can be programmed to target specific stretches of genetic code and edit DNA at precise locations. The third-generation gene editing system Streptococcus pyogenes Cas9 (SpCas9) can efficiently introduce mutations at desired target positions in the genome in a guide RNA-dependent manner .
To form a functional Cas9/gRNA complex, SpCas9 requires a gRNA consisting essentially of a CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA) . The target recognition sequence of SpCas9, called the protospacer-adjacent motif (PAM) sequence, is 5′–NGG–3′ . The system creates double-strand breaks that are repaired through non-homologous end joining (NHEJ) or homology-directed repair (HDR) pathways.
Animal Model Generation and Applications
CRISPR-Cas9 has revolutionized the generation of transgenic animals, demonstrating unprecedented efficiency, multiplexability, and ease of use, thereby reducing time and cost required for genome editing . Prior to this technology, it could take up to 18 months to produce test animals—it now takes anywhere from one-third to one-half the time to create a founder animal .
CRISPR-Cas9 technology has been used to knock out DNA in research mice and rats, meaning the animal gene for a particular target is silenced and the defective gene for human disease is knocked in . Methods used for producing animal models using fertilized embryos with the CRISPR system include microinjection, electroporation, and genome editing via oviductal nucleic acid delivery (GONAD) .
Large Animal Model Development
Small animals such as rodents do not often fully mimic key pathological changes and important symptoms of human disease, creating an emerging need to establish suitable large animal models . The CRISPR/Cas9 system is applied to establishment of large animal models, including nonhuman primates, pigs, sheep, goats and dogs, for investigating disease pathogenesis and treatment .
The first genetically modified large animals were generated in 1985, but genome editing tools like CRISPR/Cas have impacted the large animal field significantly in recent years. Simple knockouts or excision of DNA sequences can efficiently be achieved in vivo in the fertilized embryo without adverse effects on blastocyst development or sex ratio.
Advanced Editing Technologies
Recently, cytosine base editor (CBE) and adenine base editor (ABE) have been reported as new programmable base editing methods that can convert C to T or A to G at the nucleotide level . Base editors combine a nickase version of Cas9 with cytosine or adenine deaminases to convert C·G to T·A and A·T to G·C respectively .
Prime editing uses nickase Cas9 fused to reverse transcriptase and bound to a prime editing guide RNA that can theoretically install precise insertions, deletions, and all twelve types of point mutations . Prime editing technology acts like a DNA word processor to “search and replace” disease-causing genetic sequences at their precise location in the genome, without causing double-strand DNA breakage .
Therapeutic Applications and Clinical Translation
Together, cytosine and adenine base editors can theoretically correct approximately 95% of pathogenic transition mutations cataloged in ClinVar . Base editors have been successfully applied in preclinical in vivo research for more than twenty-five disorders, including more than ten rare monogenic disorders .
Prime editing technology has broad potential and could theoretically address about 90% of known disease-causing mutations across many organisms, organs and cell types . Base editing offers higher editing efficiency if the desired edit is a transition point mutation, while prime editing offers more flexibility and editing precision for all types of substitutions .
Cardiovascular Disease Applications
CRISPR-based genome editing technology has revolutionized cardiovascular research, with SpCas9 and SaCas9 broadly applied in CVD-related modeling and therapeutic purposes both in vitro and in vivo . ABEmax-NG has been shown to correct a pathogenic R404Q/+ mutation in embryos of the HCM mouse model, with administration to embryos correcting the mutant allele at rates of 62.5% to 70.8% .
Creating animal models of human cardiovascular diseases has become much easier, faster, and more flexible than ever before, greatly advancing understanding of cardiovascular pathogenesis and development of therapeutic strategies.
Delivery Methods and Technical Considerations
Base editors used for prime editing require delivery of both protein and RNA molecules into living cells, presenting significant challenges for introducing exogenous gene editing technologies into living organisms . Common delivery methods include packaging base editors into viral capsids, with adeno-associated virus (AAV) preferred for human therapies because AAV infections are largely asymptomatic .
The effective packaging capacity of AAV vectors is approximately 4.4kb, while SpCas9-reverse transcriptase fusion protein is 6.3kb, creating delivery challenges . AAV-based systems are currently the most widely used methods for delivering CRISPR-Cas components to the cardiovascular system .
Multiplexing and Complex Modifications
CRISPR-Cas9 can be used to target multiple genes simultaneously, which is an advantage that sets it apart from other gene-editing tools . Base editing allows for eight or more edits without problems, which cannot be done effectively with other methods that rely on nucleases due to unpredictability and less control .
Genome-wide screens in model organisms have been performed, accurate models of human diseases have been constructed, and potential therapies have been tested and validated in animal models . Multiple editing approaches can eliminate the need for conditioning chemotherapy in certain therapeutic applications.
Safety and Off-Target Considerations
Prime editors are immune to bystander editing and don’t exhibit Cas-independent off-target deamination, having very low off-target editing at any location in the genome that is not the target site . Prime editing involves three separate DNA binding events, suggesting fewer undesirable off-target effects than CRISPR/Cas9 .
CRISPR genome editing allows scientists to quickly create cell and animal models, which researchers can use to accelerate research into diseases. However, comprehensive safety assessment and validation remain critical for therapeutic applications.
Future Directions and Limitations
Based on remarkable progress to date, CRISPR-Cas9 technology will enable additional far-reaching advances, including understanding bases of diseases with complex genetic origins and engineering animals to produce organs for human transplantation . Advances in prime editors are directed to reduce their size, increase their efficiency, and reduce indel ratios, enhancing their therapeutic potential .
Even if animal models sometimes failed to translate to humans, genome editing has opened new opportunities in modeling human diseases with specific point mutations, copy number variants, and regulatory mutations now feasible in any genetic background and species .
Anilocus provides comprehensive CRISPR gene editing services including custom animal model generation, therapeutic target validation, and advanced editing technology implementation. Our facility offers expertise in traditional CRISPR-Cas9, base editing, and prime editing approaches with complete analytical support for verifying editing outcomes and assessing off-target effects. Our specialized capabilities include large animal model development, multiplexed editing strategies, and delivery system optimization to support translational research programs from discovery through preclinical development.
Contact us for specialized CRISPR study design and genome editing protocol development.